Who are Placebo I (Semaglutide)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): dulaglutide injection, Treatment with tirzapatide, GLP-1 RAs, NovoHelisen Depot, GLP-1 receptor agonist, exenatide (Byetta).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-i-semaglutide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo I (Semaglutide) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo I (Semaglutide) (Placebo I (Semaglutide)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Diabetes, Obesity, Cardiovascular.

phase 3 GLP-1 receptor agonist GLP-1R Diabetes, Obesity, Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Placebo I (Semaglutide) (Placebo I (Semaglutide)) — Novo Nordisk A/S. Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo I (Semaglutide) TARGET	Placebo I (Semaglutide)	Novo Nordisk A/S	phase 3	GLP-1 receptor agonist	GLP-1R
dulaglutide injection	dulaglutide injection	First Affiliated Hospital of Zhejiang University	marketed	GLP-1 receptor agonist	GLP-1R
Treatment with tirzapatide	Treatment with tirzapatide	University Medical Centre Ljubljana	marketed	GLP-1/GIP receptor agonist	GLP-1R, GIPR
GLP-1 RAs	GLP-1 RAs	Shanghai 10th People's Hospital	marketed	GLP-1 receptor agonist	GLP-1R
NovoHelisen Depot	NovoHelisen Depot	Wroclaw Medical University	marketed	GLP-1 receptor agonist	GLP-1R
GLP-1 receptor agonist	GLP-1 receptor agonist	Brigham and Women's Hospital	marketed	GLP-1 receptor agonist	GLP-1R
exenatide (Byetta)	exenatide (Byetta)	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	marketed	GLP-1 receptor agonist	GLP-1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo I (Semaglutide) — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-i-semaglutide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab